The University of Chicago Header Logo

Connection

Russell D. Cohen to Infliximab

Back to Details
This is a "connection" page, showing publications Russell D. Cohen has written about Infliximab.
Russell D. Cohen
Connection Strength
1.774
Infliximab
  1. Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis. Dig Dis Sci. 2022 03; 67(3):805-809.
    View in: PubMed
    Score: 0.203
  2. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
    View in: PubMed
    Score: 0.171
  3. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688.
    View in: PubMed
    Score: 0.158
  4. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501.
    View in: PubMed
    Score: 0.153
  5. The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 06; 61(6):1622-7.
    View in: PubMed
    Score: 0.132
  6. What is the optimal maintenance treatment for ulcerative colitis? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S236-7.
    View in: PubMed
    Score: 0.080
  7. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007 Nov; 62(11):1013-4.
    View in: PubMed
    Score: 0.075
  8. Medical therapy for ulcerative colitis: the state of the art and beyond. Curr Gastroenterol Rep. 2004 Dec; 6(6):488-95.
    View in: PubMed
    Score: 0.061
  9. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004; 64(16):1767-77.
    View in: PubMed
    Score: 0.058
  10. Infliximab at 5 years--tweaking the recipe for success? Gastroenterology. 2003 Dec; 125(6):1902-3.
    View in: PubMed
    Score: 0.057
  11. Infliximab in ulcerative colitis: is there a placebo (effect) in the house? Gastroenterology. 2003 Jun; 124(7):1990-1; discussion 1991.
    View in: PubMed
    Score: 0.055
  12. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2002 Dec; 4(6):497-505.
    View in: PubMed
    Score: 0.053
  13. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002 Aug; 35(2):151-6.
    View in: PubMed
    Score: 0.052
  14. Infliximab as first-line therapy for severe Crohn's disease? Inflamm Bowel Dis. 2002 Jan; 8(1):58-9; discussion 63-5.
    View in: PubMed
    Score: 0.050
  15. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Dig Dis. 2022; 40(5):553-564.
    View in: PubMed
    Score: 0.050
  16. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S17-22.
    View in: PubMed
    Score: 0.048
  17. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77.
    View in: PubMed
    Score: 0.047
  18. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
    View in: PubMed
    Score: 0.045
  19. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23.
    View in: PubMed
    Score: 0.029
  20. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22.
    View in: PubMed
    Score: 0.026
  21. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.021
  22. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009 Aug; 43(7):613-6.
    View in: PubMed
    Score: 0.021
  23. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex. 2006 Jul-Sep; 71(3):351-401.
    View in: PubMed
    Score: 0.017
  24. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
    View in: PubMed
    Score: 0.017
  25. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30.
    View in: PubMed
    Score: 0.017
  26. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):935-9.
    View in: PubMed
    Score: 0.017
  27. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):940-87.
    View in: PubMed
    Score: 0.017
  28. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8.
    View in: PubMed
    Score: 0.016
  29. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
    View in: PubMed
    Score: 0.015
  30. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.